• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study

    2022-04-29 06:30:28RenYiSuSunBinLingQiaoNanShanXuYongWeiRuiWangChangKuJiaLiZhuangTianShenLiMinDingZhiDanXuLaiBangLuoLiBoSunGuangMingLiTaiShiFangNanJiangKunZhangZhaoJieSuZhiHaiPengRenLangTaoJiangQiangHeLinSenYeYangYa

    Ren-Yi Su, Sun-Bin Ling, Qiao-Nan Shan , Xu-Yong Wei , Rui Wang , Chang-Ku Jia , Li Zhuang , Tian Shen , Li-Min Ding , Zhi-Dan Xu , Lai-Bang Luo , Li-Bo Sun, Guang-Ming Li , Tai-Shi Fang , Nan Jiang , Kun Zhang , Zhao-Jie Su , Zhi-Hai Peng , Ren Lang , Tao Jiang , Qiang He , Lin-Sen Ye 0 , Yang Yang 0 , Yu-Ting He , Wen-Zhi Guo , Liu-Gen Lan , Xu-Yong Sun , Dong Chen , Zhi-Shui Chen , Da-Wei Zhou , Shao-Jun Ye , Qi-Fa Ye , Min Tian , Jian-Hua Shi , Bo Wang , Jiang Liu , Qian Lu , Wei Rao , Jin-Zhen Cai , Tao Lv , Jia-Yin Yang , Pu-Sen Wang , Lin Zhong , Jing-Sheng Ma 0 , Qi-Gen Li 0 , Sheng-Dong Wu , Chang-Jiang Lu , Cai-De Lu , Dong-Hua Zhang , Xuan Wang , Zi-Qiang Li , Mu-Jian Teng , Jun-Jie Li , Wen-Tao Jiang , Jian-Hua Li , Quan-Bao Zhang , Ning-Qi Zhu , Zheng-Xin Wang , Kang He , Qiang Xia , Shao-Hua Song , Zhi-Ren Fu , Wei Qiu , Guo-Yue Lv , Rui-Peng Song , Ji-Zhou Wang , Zheng Wang 0 , Jian Zhou 0 , Gang Chen , Ying-Peng Zhao , Li Li , Ze-Min Hu , Qi-Jie Luo , Zhong-Zhou Si , Bin Xie , Xiao-Shun He , Zhi-Yong Guo , Shu-Sen Zheng , , , , Xiao Xu , , ,

    1 Department of Hepatobiliary and Pancreatic Surgery, The Center for Integrated Oncology and Precision Medicine, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou 310 0 06, China

    2 NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310 0 03, China

    3 Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou 310022, China

    4 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310 0 03, China

    5 Department of Transplantation, Jiangxi Provincial People’s Hospital Affiliated to Nanchang University, Nanchang 330 0 06, China

    6 Liver Transplantation Center, Beijing You’an Hospital, Capital Medical University, Beijing 10 0 069, China

    7 Department of Hepatic Surgery, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen 518112, China

    8 Department of General Surgery, Xiang’an Hospital of Xiamen University, Xiamen 3610 0 0, China

    9 Deartment of Hepatobiliary and Pancreaticosplenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 10 0 020, China

    10 Department of Hepatic Surgery and Liver Transplantation Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

    11 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

    12 Department of Liver Transplantation, The Second Affiliated Hospital of Guangxi Medical University, Nanning 530 0 0 0, China

    13 Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    14 Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

    15 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China

    16 Liver Transplantation Center, Tsinghua Changgung Hospital, Beijing 102218, China

    17 Organ Transplantation Center, Affiliated Hospital of Qingdao University, 59 Haier Road, Laoshan District, Qingdao 266061, China

    18 Department of Liver Surgery, Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610044, China

    19 Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 20 0 080, China

    20 Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330 0 06, China

    21 Department of Hepatobiliary and Pancreatic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo 315041, China

    22 Liver Transplant Center, General Hospital of Eastern Theater Command, Nanjing 210 0 02, China

    23 Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan 250014, China

    24 Liver Transplant Department, Tianjin First Center Hospital, Tianjin 300192, China

    25 Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 20 0 040, China

    26 Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China

    27 Liver Transplantaiton Center, Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 20 0 025, China

    28 Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun 130021, China

    29 Department of Hepatobiliary Surgery, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of USTC; Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230 0 01, China

    30 Department of Liver Surgery & Transplantation, Zhongshan Hospital Fudan University, Shanghai 20 0 032, China

    31 Department of hepato-biliary-pancreatic surgery and liver transplantation center, the First People’ s Hospital of Kunming, Kunming 650 0 0 0, China

    32 Department of Hepatobiliary Surgery, Zhongshan City People’s Hospital, Zhongshan 528499, China

    33 Department of Liver Transplantation Center, The Second Xiangya Hospital of Central South University, Changsha 410011, China

    34 Department of Hepatic Surgery and Liver Transplantation Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510062, China

    Keywords: Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

    ABSTRACT Mammalian target of rapamycin (mTOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant (LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival (RFS) in hepa- tocellular carcinoma (HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specific for the first 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefits for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese popula- tion data.

    Introduction

    Hepatocellular carcinoma (HCC) is a common malignancy with ever-growing morbidity and substantial mortality worldwide [1] . It is estimated that over half of all HCC cases and HCC-related deaths occur in China [2] . Liver transplantation (LT) is one of the most ef- fective life-saving treatments for HCC patients [3] . Compared with other surgical treatment options such as resection and ablation, LT takes its grips on conferring higher long-term survival benefits [4] .

    The immunosuppressive drugs ushered in a new dawn in the field of LT with properties of anti-rejection. However, a caveat of immunosuppression resides in the double-edged sword effects that not only reduces immunological rejection, but also adds to the risk of HCC recurrence and other complications compromising the long-term outcomes in liver recipients. Calcineurin inhibitors (CNIs), namely tacrolimus and cyclosporine, are widely used in clinical practice. Protumorigenic property is one of the primary issues of CNIs therapy. In LT rat model, both cyclosporine and tacrolimus have been shown to enhance liver tumor invasiveness and recurrence [ 5 , 6 ]. Clinically, the result is consistent with pre- clinical study and demonstrates that CNIs increase the risk of HCC recurrence after LT in a dose-dependent fashion [7] . Complica- tion such as renal insufficiency is also increased after LT, which is mainly due to the nephrotoxic effects of CNIs.

    An ideal acceptable immunosuppressant should be the one with minimal nephrotoxicity and no pro-tumorigenic effects. Recently, great attention has been bestowed to a new class of immunosup- pressive agent, mammalian target of rapamycin (mTOR) inhibitors. Sirolimus, the only approved mTOR inhibitor in China, is charac- terized with antitumorigenic effects and minimal nephrotoxicity. Mechanically,invivostudy shows that sirolimus significantly re- duces tumor growth and that this effect is mainly mediated by an- tiangiogenic effects [8] . In addition, sirolimus inhibits proliferation and migration phenotypes in HCC mice model via modulation of GP73 [9] . Another rationale is that mTOR pathway is vital in can- cer progressionperse, which has synergistic effects with antian- giogenic property to anti-hepatocarcinogenesis [10] .

    From clinical perspective, the phase 3 randomized controlled trial (RCT) named “SiLVER Study” with an 8-year follow-up period performed by Geissler et al. [11] (NCT00355862) demonstrated that sirolimus could provide a benefit of recurrence-free survival (RFS) at 3 years after transplantation, but not at the study end. Subgroup analysis showed that recipients within the Milan criteria signifi- cantly benefit in RFS during early post-LT period compared with recipients beyond the Milan criteria (no benefit across the whole period) [11] . In contrast, our previous study revealed that HCC pa- tients beyond the Milan criteria may benefit from sirolimus [12] . A recent meta-analysis included a total of 11 studies including 1 RCT testified the safety and effectiveness of sirolimus-based immuno- suppression in HCC patients following LT. The pooled results found that sirolimus-administrated recipients had lower recurrence com- pared with the control group [13] .

    As the differences exist in etiology, race, indications and proce- dures for LT between Western and Eastern models, evidence from Western studies may not be applicable in Eastern settings. Based on the experimental observations and clinical considerations, we designed a clinical trial in Chinese populations with the purpose to test whether sirolimus can improve RFS in LT patients. We pre- dict an improved RFS in LT patients treated with sirolimus.

    Methods/design

    Basic protocol overview

    This is an open-labeled, single-arm, prospective multicenter, real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in patients undergoing LT for HCC. We have named the trial the “LEAP-Sirolimus (LEAPS)”(ChiCTR210 0 042869) with a double meaning. Firstly, it refers to a combination of the sirolimus and name of our organization, namely Liver Elite Aspiration Network 9Plus. Secondly, “LEAPS”contains our expectation and prediction for giant leaps to be made in this trial. The study is planned for 4 years in total with a 2- year enrollment period and a 2-year follow-up ( Fig. 1 ). Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center- specific for the first 4-6 weeks. The following regimens integrate sirolimus into the regimens as a combination therapy with reduced CNI based on the condition of patients and centers.

    Fig. 1. Study scheme of LEAPS trial. LT: liver transplantation; HCC: hepatocellular carcinoma; HIV: human immunodeficiency virus; mTOR: mammalian target of rapamycin; MPA: mycophenolate mofetil; CNIs: calcineurin inhibitors.

    Notably, patients are not prohibited to use antitumor drugs in- cluding traditional chemotherapies, immunotherapies and target drugs, but detailed records of type, dosage and duration of med- ication are warranted.

    Inclusion criteria

    The trial enrolls all patients eligible for LT as listed by each of the participating centers. The specific inclusion criteria are as follows: age between 18 and 70 years, histologically proven HCC before early switch to sirolimus-based regimens, written informed consent given by the patient. Another inclusion criterion is accep- tance of both deceased liver donors and living liver donors. We only include patients beyond the Milan criteria at the time of LT but without macrovascular invasion (expect for branch of portal vein) and distant metastasis. One caveat is that the latter shall pre- vail when divergences emerge between pre-LT diagnosis and post- LT pathology.

    Exclusion criteria

    Patients meeting one of the following criteria are excluded: multiple-organ recipients, patients known to be hypersensitive to sirolimus or its derivates, hyperlipidemia refractory to optimal medical treatment (triglyceride ≥400 mg/dL or ≥4.6 mmol/L, to- tal cholesterol ≥300 mg/dL or ≥7.8 mmol/L), evidence of local or systemic infection, human immunodeficiency virus-positive pa- tients, platelets counts<35 × 109/L, white blood cell counts<1.5 × 109/L, urine routine: protein ++ or beyond, women who are pregnant, lactating or child-bearing potential not willing to take contraception, patients with history of non-HCC tumor within 5 years prior to inclusion (basal cell and squamous cell skin cancers that have been successfully treated are not included), patients with a psychological, familial, sociologic or geographic condition difficult to comply with study protocol or follow-up schedule, and under guardianship (e.g. individuals who are not able to freely give their informed consent).

    Withdrawal criteria

    Participants who meet the withdrawal criteria will be with- drawn from the study but not replaced. The withdrawal criteria for this study are as follows: participants who actively request to withdraw from the study (retract/revoke informed consent), lost to follow-up, taking medications prohibited for the trial, with a history of allergic reaction to sirolimus or its additives, pregnant, violating trial protocol, subjects censored at death, clinical cases when physicians in charge believe that continued participation in the study is not in the best interest of the patient considering any pathological event, clinical adverse event, or change in the sub- ject’s physical condition, and other reasons to be withdrawn from the study.

    Study objectives

    We predict that this sirolimus-based regimen will improve HCC-free survival in LT population. The primary endpoint of this study is the occurrence of metastasis and/or recurrence after LT procedure. Secondary endpoints include tumor-related death, inci- dence of allograft rejection, graft loss and alterations in renal func- tion.

    Treatment scheme

    Patients are treated with center-specific immunosuppressive protocol for the first 4-6 weeks, excluding use of any mTOR- inhibitor medications. The initial immunosuppressant regimens in- clude CNIs ± mycophenolic acid (MPA) ± glucocorticoid immuno- suppressant ± IL-2 inhibitor (basiliximab) regimen. Tacrolimus is preferred in CNIs drugs. MPA drugs can be Cellcept (MMF) or My- fortic (EC-MPS). Four to ten ng/mL for sirolimus and 50% reduction in CNIs are recommended but not strictly restricted. The choice of regimen and dose of drugs should be based on the condition of patients and centers. Our only requirement is comprising sirolimus conversion regimen including the use of sirolimus starting between day 29 and day 42 after LT and a simultaneous reduction in CNIs.

    Follow-up and documentation

    All patients enrolled in the study will be followed up at least 7 times in 2 years. Follow-up examinations will be done on second and third month, then every 3 months to the end of first year and every 6 months to the end of second year.

    The management of the data in the study is performed using the Electronic Data Capture (EDC) system. Trial data will be col- lected through the electronic case record form (eCRF). Regular doc- umentations include evaluation of symptoms and signs, monitor- ing the trough concentrations of CNIs and sirolimus, patient recur- rence/metastasis information and patient survival, changes in re- nal function, concomitant medication (e.g., type, dosage and du- ration) and adverse event information. Lost-to-follow-up is de- fined as missing two consecutive follow-up visits. If the last con- tact is prior to the diagnosis of a recurrence/metastasis event, recurrence/metastasis-free survival time is censored using the date of the last contact. If patient can be re-contacted, the status should be reset to alive. Notably, recurrence/metastasis-free survival time and corresponding censoring status will remain. If definite date of a patient’s death is documented, the status will be "dead".

    Endpoint definition

    The definition of HCC RFS is the time interval between the first date of LT and the date of HCC recurrence/metastasis or death; censored for RFS will be made for patients alive or recurrence-free at the time of their last contact. HCC recur- rence/metastasis is defined as either histologically confirmed tu- mor recurrence/metastasis, or unequivocal evidence according to the Barcelona Criteria (Barcelona-20 0 0 EASL Conference). Date of recurrence is defined as the first day of tumor suspicion. Clinical evidence for HCC recurrence includes symptoms and signs (e.g., pruritis and ascites), laboratory examination [e.g., alpha-fetoprotein (AFP) and PIVKA-II], liver image by computerized tomography or magnetic resonance imaging, as well as diagnostic action of Barcelona Criteria. Recurrence of HCC can therefore be evaluated through the whole follow-up period besides the protocol required visits.

    Trial organization

    The study is an investigator-initiated trial. Preliminary inves- tigator meetings to plan the details of the trial protocol were organized by Shulan (Hangzhou) Hospital and Hangzhou First People’s Hospital. Services for site monitoring, data management and arranging regulatory affairs are provided by experts familiar with the trial in Shulan (Hangzhou) Hospital and Hangzhou First People’s Hospital. Statistical research is performed within Shulan (Hangzhou) Hospital, Hangzhou First People’s Hospital and China Liver Transplant Registry.

    Participating centers

    Major liver transplant centers from different provinces are par- ticipating this clinical trial. In total, 33 sites covering most parts of China up to 19 provinces have committed to participate the study.

    Drug supply

    One mg sirolimus (Rapamune) blisters produced by Pfizer Ire- land Pharmaceuticals (Little Connell, Newbridge, Co. Kildare, Ire- land) is used as study medication in participating centers.

    Quality control and on-site monitoring

    Quality control is performed across whole process of the study including screening and determination of eligibility of research centers, laboratory and researchers to fully meet requirements of the national law “Quality Management Practice for Medical Device Clinical Trials” in China. Recruitment and follow-up of patients, regular monitoring of safety and endpoint data are performed ac- cording to good clinical practice (GCP) guidelines. Data manage- ment is performed by each center and documentations from clini- cal trials are maintained and managed in accordance with the GCP requirements.

    Ethics and safety

    Protocol version 1 has been reviewed and approved by the re- sponsible Institutional Review Board/Institutional Ethics Commit- tee (IRB/IEC) for all of centers. The study protocol complies with theDeclarationofHelsinkiand principles of the GCP guidelines. Written informed consent is obtained from all participants at en- rollment. Each patient is fully informed about the procedure of the trial and liable reasonable risk by an experienced physician famil- iar with the study. The safety and all potential side effects for the patients are monitored at least once a year by IRB/IEC. Qualified personnel from all sites should also attend meeting regularly to review safety data, including adverse events and serious adverse events. Any information deemed to potentially affect the safety of the trial should be reported to IRB/IEC in time.

    Statistical analysis

    A one-sided, one-sample log-rank test calculated from a sample of 397 subjects achieves 90.1% power at a 0.025 significance level to detect a median survival time of 1.20-fold in the new group when the median survival time of the historic control group is 1.00. Subjects are accrued for 2.0 years. Follow-up that continues for 2 years after the last subject is added. The probability of a sub- ject experiencing an event during the study is 0.8132. The expected number of events during the study is 323. It is assumed that the survival time distributions of both groups are approximated rea- sonably well by the Weibull distribution with a shape parameter of 1.00.

    Demographic and clinical characteristics of participants are summarized using standard descriptive statistics. Time-to-event end points including RFS, overall survival (OS) and tumor-related death are assessed at the end of the study estimated by the Kaplan-Meier method. As part of the secondary analysis, we mainly focus on the alterations in renal function as its potential renal protective effect. Further stratified analyses are performed on the stratification of adjuvant therapy. Safety parameters for inci- dence of adverse events are analyzed based on the safety analysis set which is defined as subjects who receive at least one dose of study drug. All continuous variables are compared by Student’st- test or rank-sum test and rate is compared by Chi-square test.

    Discussion

    There are two substantial issues in patients undergoing LT pro- cedure for HCC: graft rejection and tumor recurrence. Recent stud- ies have shown that sirolimus bears a potential antitumorigenic ef- fects [ 6 , 9 , 10 ]. The SiLVER study is the first RCT trial which eval- uates HCC recurrence in LT recipients [11] . Results by the confir- matory analysis of the SiLVER-trial in 2016 have drawn three im- portant conclusions. Firstly, sirolimus conversion does not improve long-term RFS beyond 5 years in LT recipients with HCC. Secondly, younger (age ≤60 years), low-risk (within the Milan criteria) re- cipients and patients with sirolimus monotherapy also benefited from sirolimus treatment. Thirdly, no contraindicative overall dis- advantage regarding serious adverse events of sirolimus therapy became apparent during the trial. The trial lays the foundation for applying sirolimus-based immunosuppressive regimen to LT pa- tients with HCC and provides a reasonable clinical rationale for our study. Although sirolimus treatment provides a survival advantage up to 5 years after transplantation, it seems ambiguous for the an- titumor effect as it’s diminishing RFS benefits. More recently, the SiLVER-trial published its data with exploratory approach revealing a clearer antitumor effect [14] . The analysis included data from 508 patients with a follow-up period of 72.4 months on average. Mul- tivariate analysis showed an independent benefit of sirolimus use for ≥3 months for OS. Subgroup analysis demonstrated that the patients deriving the maximum benefit reside in those with AFP ≥10 ng/mL and having used sirolimus for ≥3 months with regard to OS, disease-free survival, and HCC recurrence. Higher tumor ac- tivity in LT patients with AFP evidence is advocated for mTOR in- hibitor use.

    Here, we put forward three key issues to consider when design- ing this trial. The first consideration is that our study population only includes LT patients with HCC (beyond the Milan criteria) and without macrovascular invasion (expect for branch of portal vein) and distant metastasis. This trial is a continuation of our previous work that revealed recipients exceeding, rather than meeting, the Milan criteria may benefit from sirolimus [12] . Among recipients beyond the Milan criteria, our unpublished data suggest a signif- icant survival benefit in branch invasion of portal vein compared with major portal vein invasion. And we have observed compara- ble prognosis between the branch invasion of portal vein group and without macrovascular invasion group. Our reasoning is that particular patients beyond the Milan criteria and with branch in- vasion of portal vein may benefit most from sirolimus conversion regimen, similar to the finding that higher tumor activity in LT may benefit from sirolimus use as declared in SiLVER study. Ad- ditionally, choosing RFS as our primary endpoint is another critical point. According to the published data from SiLVER study, encour- aging results demonstrate a clear antitumor effect particularly in patients with AFP ≥10 ng/mL and having used sirolimus for ≥3 months. In our study, we assert a similar benefit of sirolimus in prognosis (e.g., lower recurrence rate, later tumor redevelopment, longer survival time after recurrence). Thus, single-arm trial using sirolimus conversion is preferred after intense debate for ethical considerations. Final issue to consider is that our study is aimed to provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data. A limita- tion of the trial is the intrinsic disadvantage of single-arm study. Without simultaneous control, it may undermine the credibility of research as the survival rate of recipients undergoing LT procedure may be higher than the counterpart in previous studies regard- ing the development of antitumor drugs, surgery technology and medical conditions. Essentially, we prospectively assess the clinical value of sirolimus in a real-world setting without prohibiting ad- ditional therapy (e.g., immunotherapies and target drugs) to bet- ter reflect the actual clinical benefits for LT recipients beyond the Milan criteria. We expect to provide multiple immunosuppressant regimens for clinicians and patients in the clinical scenario.

    The LEAPS study is the first open-labeled, single-arm, prospec- tive multicenter, real-world trial based on Chinese population that primarily evaluates HCC recurrence in LT recipients beyond the Milan criteria. We predict that sirolimus conversion regimen will provide survival benefits for patients particular in the key indica- tor “RFS” as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator “OS”.

    Acknowledgments

    The authors would like to dedicate this article to the memory of the late Yun-Jin Zang, the esteemed pioneer in the field of liver transplantation for his inspiration and assistance in initiating this clinical trial.

    CRediT authorship contribution statement

    Ren-YiSu:Conceptualization, Visualization, Writing - original draft.Sun-BinLing:Conceptualization, Writing - review & editing.Qiao-NanShan:Conceptualization, Project administration, Data curation, Writing - review & editing.Xu-YongWei:Conceptualiza- tion, Project administration, Data curation, Writing - review & edit- ing.RuiWang: Methodology, Formal analysis, Software, Writing - review & editing.Chang-KuJia:Conceptualization, Project ad- ministration, Data curation, Writing - review & editing.LiZhuang:Conceptualization, Project administration, Data curation, Writing - review & editing.TianShen:Conceptualization, Project adminis- tration, Data curation, Writing - review & editing.Li-MinDing:Conceptualization, Project administration, Data curation, Writing - review & editing.Zhi-DanXu:Conceptualization, Project adminis- tration, Data curation, Writing - review & editing.Lai-BangLuo:Conceptualization, Project administration, Data curation, Writing - review & editing.Li-BoSun:Conceptualization, Project administra- tion, Data curation, Writing - review & editing, Writing - review & editing.Guang-MingLi:Conceptualization, Project administration, Data curation, Writing - review & editing.Tai-ShiFang:Conceptu- alization, Project administration, Data curation, Writing - review & editing.NanJiang:Conceptualization, Project administration, Data curation, Writing - review & editing.KunZhang:Conceptualiza- tion, Project administration, Data curation, Writing - review & edit- ing.Zhao-JieSu:Conceptualization, Project administration, Data curation, Writing - review & editing.Zhi-HaiPeng:Conceptual- ization, Project administration, Data curation, Writing - review & editing.RenLang:Conceptualization, Project administration, Data curation, Writing - review & editing.TaoJiang:Conceptualiza- tion, Project administration, Data curation, Writing - review & edit- ing.QiangHe:Conceptualization, Project administration, Data cu- ration, Writing - review & editing.Lin-SenYe:Conceptualization, Project administration, Data curation, Writing - review & editing.YangYang:Conceptualization, Project administration, Data cura- tion, Writing - review & editing.Yu-TingHe:Conceptualization, Project administration, Data curation, Writing - review & editing.Wen-ZhiGuo:Conceptualization, Project administration, Data cu- ration, Writing - review & editing.Liu-GenLan:Conceptualization, Project administration, Data curation, Writing - review & editing.Xu-YongSun:Conceptualization, Project administration, Data cu- ration, Writing - review & editing.DongChen:Conceptualization, Project administration, Data curation, Writing - review & editing.Zhi-ShuiChen:Conceptualization, Project administration, Data cu- ration, Writing - review & editing.Da-WeiZhou:Conceptualiza- tion, Project administration, Data curation, Writing - review & edit- ing.Shao-JunYe:Conceptualization, Project administration, Data curation, Writing - review & editing.Qi-FaYe:Conceptualization, Project administration, Data curation, Writing - review & edit- ing.MinTian:Conceptualization, Project administration, Data cu- ration, Writing - review & editing.Jian-HuaShi:Conceptualization, Project administration, Data curation, Writing - review & editing.BoWang:Conceptualization, Project administration, Data curation, Writing - review & editing.JiangLiu:Conceptualization, Project administration, Data curation, Writing - review & editing.QianLu:Conceptualization, Project administration, Data curation, Writing - review & editing.WeiRao:Conceptualization, Project administra- tion, Data curation, Writing - review & editing.Jin-ZhenCai:Con- ceptualization, Project administration, Data curation, Writing - re- view & editing.TaoLv:Conceptualization, Project administration, Data curation, Writing - review & editing.Jia-YinYang:Concep- tualization, Project administration, Data curation, Writing - review & editing.Pu-SenWang:Conceptualization, Project administration, Data curation, Writing - review & editing.LinZhong:Conceptu- alization, Project administration, Data curation, Writing - review & editing.Jing-ShengMa:Conceptualization, Project administra- tion, Data curation, Writing - review & editing.Qi-GenLi:Con- ceptualization, Project administration, Data curation, Writing - re- view & editing.Sheng-DongWu:Conceptualization, Project ad- ministration, Data curation, Writing - review & editing.Chang-JiangLu:Conceptualization, Project administration, Data curation, Writing - review & editing.Cai-DeLu:Conceptualization, Project administration, Data curation, Writing - review & editing.Dong-HuaZhang:Conceptualization, Project administration, Data cura- tion, Writing - review & editing.XuanWang:Conceptualization, Project administration, Data curation, Writing - review & editing.Zi-QiangLi:Conceptualization, Project administration, Data cura- tion, Writing - review & editing.Mu-JianTeng:Conceptualiza- tion, Project administration, Data curation, Writing - review & edit- ing.Jun-JieLi:Conceptualization, Project administration, Data cu- ration, Writing - review & editing.Wen-TaoJiang:Conceptualiza- tion, Project administration, Data curation, Writing - review & edit- ing.Jian-HuaLi:Conceptualization, Project administration, Data curation, Writing - review & editing.Quan-BaoZhang:Concep- tualization, Project administration, Data curation, Writing - review & editing.Ning-QiZhu:Conceptualization, Project administration, Data curation, Writing - review & editing.Zheng-XinWang:Con- ceptualization, Project administration, Data curation, Writing - re- view & editing.KangHe:Conceptualization, Project administration, Data curation, Writing - review & editing.QiangXia:Conceptu- alization, Project administration, Data curation, Writing - review & editing.Shao-HuaSong:Conceptualization, Project administra- tion, Data curation, Writing - review & editing.Zhi-RenFu:Con- ceptualization, Project administration, Data curation, Writing - re- view & editing.WeiQiu:Conceptualization, Project administration, Data curation, Writing - review & editing.Guo-YueLv:Conceptu- alization, Project administration, Data curation, Writing - review & editing.Rui-PengSong:Conceptualization, Project administration, Data curation, Writing - review & editing.Ji-ZhouWang:Con- ceptualization, Project administration, Data curation, Writing - re- view & editing.ZhengWang:Conceptualization, Project adminis- tration, Data curation, Writing - review & editing.JianZhou:Con- ceptualization, Project administration, Data curation, Writing - re- view & editing.GangChen:Conceptualization, Project administra- tion, Data curation, Writing - review & editing.Ying-PengZhao:Conceptualization, Project administration, Data curation, Writing - review & editing.LiLi:Conceptualization, Project administration, Data curation, Writing - review & editing.Ze-MinHu:Conceptu- alization, Project administration, Data curation, Writing - review & editing.Qi-JieLuo:Conceptualization, Project administration, Data curation, Writing - review & editing.Zhong-ZhouSi:Conceptu- alization, Project administration, Data curation, Writing - review & editing.BinXie:Conceptualization, Project administration, Data curation, Writing - review & editing.Xiao-ShunHe:Conceptual- ization, Project administration, Data curation, Writing - review & editing.Zhi-YongGuo:Conceptualization, Project administration, Data curation, Writing - review & editing.Shu-SenZheng:Con- ceptualization, Supervision, Writing - review & editing.XiaoXu:Conceptualization, Supervision, Funding acquisition, Writing - re- view & editing.

    Funding

    This study was supported by grants from the National S&T Ma- jor Project (2017ZX10203205), Key Program, National Natural Sci- ence Foundation of China ( 81930016 ) and Zhejiang Provincial Nat- ural Science Foundation of China (LY21H160026).

    Ethical approval

    This study was reviewed and approved by the Institutional Re- view Board/Institutional Ethics Committee in each center.

    Competing interest

    No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the sub- ject of this article.

    天堂网av新在线| 少妇熟女欧美另类| 中文字幕免费在线视频6| 国产高清三级在线| 欧美日韩一区二区视频在线观看视频在线 | 九九在线视频观看精品| www日本黄色视频网| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 午夜福利在线观看免费完整高清在| 日韩欧美 国产精品| 成人三级黄色视频| АⅤ资源中文在线天堂| 久久久色成人| 一个人观看的视频www高清免费观看| 最近手机中文字幕大全| 免费黄网站久久成人精品| 亚洲精华国产精华液的使用体验| 在线观看av片永久免费下载| 国产一区二区在线av高清观看| 嫩草影院入口| av线在线观看网站| 日韩国内少妇激情av| 日韩一本色道免费dvd| 国产成人91sexporn| 国产精品精品国产色婷婷| 男女边吃奶边做爰视频| 午夜精品在线福利| 亚洲精品一区蜜桃| 国产老妇女一区| 国语自产精品视频在线第100页| 日本黄色视频三级网站网址| 日韩一本色道免费dvd| 男女下面进入的视频免费午夜| 国产视频首页在线观看| 秋霞在线观看毛片| 欧美变态另类bdsm刘玥| 亚洲激情五月婷婷啪啪| 久久久精品94久久精品| 国产亚洲av嫩草精品影院| 欧美成人免费av一区二区三区| 久久这里有精品视频免费| 看十八女毛片水多多多| 99久久精品热视频| 成人无遮挡网站| 久热久热在线精品观看| 国产探花极品一区二区| 国产精品无大码| 国产一区二区在线av高清观看| 国产在视频线精品| 别揉我奶头 嗯啊视频| 内射极品少妇av片p| 亚洲精品亚洲一区二区| АⅤ资源中文在线天堂| 国产人妻一区二区三区在| av在线老鸭窝| 日本黄色视频三级网站网址| 国产精品一区二区三区四区久久| 中文乱码字字幕精品一区二区三区 | 国产在线一区二区三区精 | 变态另类丝袜制服| 老司机影院成人| 天堂影院成人在线观看| 在线天堂最新版资源| 国产一区二区在线观看日韩| 国产成人a∨麻豆精品| 嘟嘟电影网在线观看| 日韩在线高清观看一区二区三区| 免费看a级黄色片| 欧美一区二区国产精品久久精品| 99热全是精品| 国产精品99久久久久久久久| 黄片wwwwww| 亚洲av电影在线观看一区二区三区 | 精品国产三级普通话版| 欧美成人a在线观看| 成人二区视频| 黄色一级大片看看| 99热网站在线观看| 一区二区三区免费毛片| 国产亚洲av片在线观看秒播厂 | 亚洲第一区二区三区不卡| 99热网站在线观看| 好男人视频免费观看在线| 欧美高清性xxxxhd video| 日韩国内少妇激情av| 亚洲精品,欧美精品| 国产精品三级大全| 秋霞在线观看毛片| 欧美人与善性xxx| 自拍偷自拍亚洲精品老妇| 国产亚洲最大av| 国产精品美女特级片免费视频播放器| 亚洲精华国产精华液的使用体验| 亚洲成人精品中文字幕电影| 中文字幕熟女人妻在线| 啦啦啦啦在线视频资源| 白带黄色成豆腐渣| 国产精品国产三级国产av玫瑰| 日韩高清综合在线| 亚洲丝袜综合中文字幕| 亚洲精品日韩在线中文字幕| 少妇裸体淫交视频免费看高清| 建设人人有责人人尽责人人享有的 | 国产高清不卡午夜福利| 99久久中文字幕三级久久日本| 国语对白做爰xxxⅹ性视频网站| 亚洲欧美精品综合久久99| 亚洲欧美清纯卡通| 青春草国产在线视频| 看片在线看免费视频| 大话2 男鬼变身卡| 中文字幕熟女人妻在线| 99热这里只有精品一区| 在线a可以看的网站| 精品一区二区免费观看| 午夜精品在线福利| 久久亚洲国产成人精品v| 亚洲精品日韩在线中文字幕| 欧美zozozo另类| 18禁动态无遮挡网站| 我的女老师完整版在线观看| 久久国内精品自在自线图片| 99久久精品一区二区三区| 国产免费福利视频在线观看| 噜噜噜噜噜久久久久久91| 久久人人爽人人片av| 97超碰精品成人国产| av在线观看视频网站免费| 噜噜噜噜噜久久久久久91| 麻豆av噜噜一区二区三区| 欧美日韩国产亚洲二区| 久久婷婷人人爽人人干人人爱| 天天躁日日操中文字幕| 啦啦啦观看免费观看视频高清| 欧美一区二区精品小视频在线| 久久久久久国产a免费观看| 非洲黑人性xxxx精品又粗又长| 18+在线观看网站| 日本五十路高清| 我要搜黄色片| 高清毛片免费看| 你懂的网址亚洲精品在线观看 | 成年av动漫网址| 成年版毛片免费区| 亚洲熟妇中文字幕五十中出| 成年免费大片在线观看| .国产精品久久| 高清日韩中文字幕在线| 国产精品一区www在线观看| 国产午夜精品一二区理论片| 看非洲黑人一级黄片| 亚洲婷婷狠狠爱综合网| 国产激情偷乱视频一区二区| 97人妻精品一区二区三区麻豆| 欧美激情在线99| 日本三级黄在线观看| 欧美三级亚洲精品| 国产精品女同一区二区软件| 久久久久久久久久久丰满| 久久精品91蜜桃| 国产成人福利小说| 成人亚洲精品av一区二区| 国产精品1区2区在线观看.| 国产欧美另类精品又又久久亚洲欧美| 国产精品国产三级国产专区5o | 春色校园在线视频观看| 小蜜桃在线观看免费完整版高清| 少妇丰满av| 97热精品久久久久久| 午夜精品一区二区三区免费看| 中文天堂在线官网| 国产精品爽爽va在线观看网站| 超碰97精品在线观看| 看十八女毛片水多多多| 男女国产视频网站| 亚洲国产精品久久男人天堂| 国产乱人视频| 日韩av在线大香蕉| 欧美变态另类bdsm刘玥| 国产精品久久久久久精品电影| 最后的刺客免费高清国语| 国产色爽女视频免费观看| 成人毛片a级毛片在线播放| 激情 狠狠 欧美| 国产精品伦人一区二区| 国产熟女欧美一区二区| 变态另类丝袜制服| 蜜桃久久精品国产亚洲av| 久久精品91蜜桃| 淫秽高清视频在线观看| 又爽又黄a免费视频| 成人毛片a级毛片在线播放| 偷拍熟女少妇极品色| 一卡2卡三卡四卡精品乱码亚洲| 欧美区成人在线视频| 国产av不卡久久| 人妻系列 视频| 九草在线视频观看| 亚洲av福利一区| 非洲黑人性xxxx精品又粗又长| 久久鲁丝午夜福利片| 亚洲av男天堂| 久久99热6这里只有精品| 国产毛片a区久久久久| 久久久久久久久久黄片| 国产精品久久久久久久久免| 欧美日韩综合久久久久久| 九色成人免费人妻av| 国产亚洲一区二区精品| 国产精品一区二区性色av| av在线天堂中文字幕| 内地一区二区视频在线| 日韩av不卡免费在线播放| 久久6这里有精品| 最近最新中文字幕大全电影3| 中文天堂在线官网| 六月丁香七月| 91精品一卡2卡3卡4卡| 99久久精品热视频| 国产视频内射| 你懂的网址亚洲精品在线观看 | 色综合色国产| 国产精品爽爽va在线观看网站| 蜜桃久久精品国产亚洲av| 中文天堂在线官网| 丰满少妇做爰视频| 中国美白少妇内射xxxbb| 久久这里只有精品中国| 久久久久性生活片| 久久久久久久久久久免费av| 深爱激情五月婷婷| 亚洲天堂国产精品一区在线| 欧美日韩在线观看h| 丰满少妇做爰视频| 久久鲁丝午夜福利片| 亚洲av福利一区| 蜜桃亚洲精品一区二区三区| 成人毛片a级毛片在线播放| 岛国在线免费视频观看| 国产伦精品一区二区三区四那| av免费观看日本| 午夜精品在线福利| 视频中文字幕在线观看| 日韩欧美精品免费久久| 人人妻人人看人人澡| 搡女人真爽免费视频火全软件| 亚洲国产色片| 九九在线视频观看精品| 免费大片18禁| 久久精品熟女亚洲av麻豆精品 | 色噜噜av男人的天堂激情| 欧美色视频一区免费| 搞女人的毛片| 国产一区二区亚洲精品在线观看| 久久久久久久国产电影| 国产高潮美女av| 最近中文字幕高清免费大全6| 大又大粗又爽又黄少妇毛片口| 看非洲黑人一级黄片| 成人av在线播放网站| www.av在线官网国产| 日本猛色少妇xxxxx猛交久久| 欧美成人免费av一区二区三区| 毛片女人毛片| 日本免费a在线| 成人美女网站在线观看视频| 九九久久精品国产亚洲av麻豆| 国产精品美女特级片免费视频播放器| 欧美日韩一区二区视频在线观看视频在线 | 麻豆一二三区av精品| 精品一区二区免费观看| 中文字幕亚洲精品专区| 国产极品天堂在线| 亚洲欧美中文字幕日韩二区| 精品国产一区二区三区久久久樱花 | 在现免费观看毛片| 伦精品一区二区三区| 中文精品一卡2卡3卡4更新| 91精品国产九色| 成人毛片60女人毛片免费| 国产成人a∨麻豆精品| 在线播放无遮挡| 免费不卡的大黄色大毛片视频在线观看 | 国产精品伦人一区二区| 欧美又色又爽又黄视频| 99在线视频只有这里精品首页| 国产白丝娇喘喷水9色精品| 噜噜噜噜噜久久久久久91| 真实男女啪啪啪动态图| 久久亚洲精品不卡| 国产精华一区二区三区| 日韩在线高清观看一区二区三区| 亚洲国产欧洲综合997久久,| 国产综合懂色| 亚洲欧洲国产日韩| 国产麻豆成人av免费视频| 国产激情偷乱视频一区二区| 最近最新中文字幕免费大全7| 国产黄色视频一区二区在线观看 | 综合色丁香网| 18+在线观看网站| 亚洲av免费在线观看| 亚洲欧美精品综合久久99| 男女啪啪激烈高潮av片| 国产精品久久久久久精品电影小说 | 国产欧美另类精品又又久久亚洲欧美| 亚洲精品一区蜜桃| 黄片wwwwww| 麻豆乱淫一区二区| 亚洲精品aⅴ在线观看| 国模一区二区三区四区视频| 99久久九九国产精品国产免费| 中文字幕熟女人妻在线| 精品久久久久久久人妻蜜臀av| 我的女老师完整版在线观看| 亚洲精品一区蜜桃| 草草在线视频免费看| 成年免费大片在线观看| 国产av在哪里看| 亚洲欧美日韩高清专用| 在线天堂最新版资源| 91久久精品国产一区二区成人| 久久亚洲国产成人精品v| 一边亲一边摸免费视频| 99热这里只有是精品50| 免费播放大片免费观看视频在线观看 | 亚洲丝袜综合中文字幕| 欧美精品国产亚洲| 久久久a久久爽久久v久久| 婷婷色综合大香蕉| 男人狂女人下面高潮的视频| 国产三级在线视频| 久久久久性生活片| 午夜福利在线在线| 一级黄片播放器| 两个人的视频大全免费| 久久国内精品自在自线图片| 欧美三级亚洲精品| 午夜福利视频1000在线观看| 色网站视频免费| 狠狠狠狠99中文字幕| 国产又色又爽无遮挡免| 亚洲国产欧美人成| 中文字幕久久专区| 五月玫瑰六月丁香| 午夜精品一区二区三区免费看| 免费av毛片视频| 晚上一个人看的免费电影| 人人妻人人澡欧美一区二区| 少妇熟女欧美另类| 日产精品乱码卡一卡2卡三| av女优亚洲男人天堂| 欧美日韩一区二区视频在线观看视频在线 | 九草在线视频观看| 女人十人毛片免费观看3o分钟| 伦精品一区二区三区| 亚洲最大成人av| 国产色婷婷99| 国产亚洲91精品色在线| 国产探花在线观看一区二区| АⅤ资源中文在线天堂| 国产精品电影一区二区三区| 99在线人妻在线中文字幕| 亚洲人成网站高清观看| 亚洲国产欧美在线一区| 国产日韩欧美在线精品| 亚洲av福利一区| 久久人妻av系列| 亚洲综合色惰| 日韩欧美国产在线观看| 国产精品国产三级国产av玫瑰| 在线播放国产精品三级| 高清日韩中文字幕在线| 十八禁国产超污无遮挡网站| 色吧在线观看| 十八禁国产超污无遮挡网站| 五月玫瑰六月丁香| 久久精品熟女亚洲av麻豆精品 | 国产高清国产精品国产三级 | 国产亚洲午夜精品一区二区久久 | 18禁动态无遮挡网站| 国产三级在线视频| 国产一级毛片在线| 亚洲成人中文字幕在线播放| 亚洲av不卡在线观看| 精品人妻视频免费看| 99热这里只有是精品在线观看| 波多野结衣高清无吗| 午夜激情欧美在线| 免费看a级黄色片| 又爽又黄a免费视频| 亚洲精品乱码久久久久久按摩| 简卡轻食公司| 亚洲精品日韩在线中文字幕| a级毛色黄片| 亚洲av中文av极速乱| 午夜激情欧美在线| 日本与韩国留学比较| 人妻系列 视频| 亚洲真实伦在线观看| 秋霞在线观看毛片| 黄片无遮挡物在线观看| 亚洲精品456在线播放app| 久久国产乱子免费精品| 精品久久久久久成人av| 色综合亚洲欧美另类图片| 亚洲精品乱码久久久v下载方式| 久久久精品94久久精品| 国产综合懂色| 又粗又硬又长又爽又黄的视频| 99热这里只有是精品50| 麻豆国产97在线/欧美| 欧美潮喷喷水| 九九热线精品视视频播放| 少妇的逼水好多| 久久久久久久午夜电影| 亚洲成av人片在线播放无| 国产高清国产精品国产三级 | 欧美性感艳星| 国产免费男女视频| 狠狠狠狠99中文字幕| 午夜视频国产福利| 亚洲欧洲日产国产| 日韩一区二区视频免费看| 日韩大片免费观看网站 | 亚洲国产精品久久男人天堂| 亚洲精品乱码久久久久久按摩| 99国产精品一区二区蜜桃av| 免费人成在线观看视频色| 久久欧美精品欧美久久欧美| 视频中文字幕在线观看| 免费人成在线观看视频色| 欧美日韩精品成人综合77777| 1024手机看黄色片| 亚洲av二区三区四区| 91在线精品国自产拍蜜月| 日韩欧美在线乱码| 亚洲av电影在线观看一区二区三区 | 久久99热这里只有精品18| 欧美高清性xxxxhd video| 免费播放大片免费观看视频在线观看 | 国产精品永久免费网站| www.色视频.com| 国产乱人偷精品视频| 精品国产三级普通话版| 国产av一区在线观看免费| www.色视频.com| 精品久久久久久久久久久久久| 亚洲怡红院男人天堂| 乱码一卡2卡4卡精品| 国产精品人妻久久久影院| 99久久精品一区二区三区| 听说在线观看完整版免费高清| 国产伦在线观看视频一区| 成人午夜高清在线视频| 精品不卡国产一区二区三区| 成人性生交大片免费视频hd| 亚洲欧美精品专区久久| 精品久久久久久成人av| 国产一区亚洲一区在线观看| 国产成人午夜福利电影在线观看| av视频在线观看入口| 小说图片视频综合网站| 国产人妻一区二区三区在| 久久99精品国语久久久| 午夜福利成人在线免费观看| 七月丁香在线播放| 国产伦精品一区二区三区四那| 国产精品女同一区二区软件| 波野结衣二区三区在线| 日本欧美国产在线视频| 亚洲av中文av极速乱| 嘟嘟电影网在线观看| 色综合亚洲欧美另类图片| 日韩视频在线欧美| 偷拍熟女少妇极品色| 国产白丝娇喘喷水9色精品| 美女cb高潮喷水在线观看| 91久久精品电影网| 麻豆av噜噜一区二区三区| 精品国产三级普通话版| 国产色婷婷99| 欧美性感艳星| 在线a可以看的网站| 麻豆成人午夜福利视频| 中文欧美无线码| 久久久久久久久久久丰满| 国产av不卡久久| 中国美白少妇内射xxxbb| 久久韩国三级中文字幕| 国产免费一级a男人的天堂| 国产精品一二三区在线看| 男女下面进入的视频免费午夜| 日本一本二区三区精品| 国产精品精品国产色婷婷| 国产白丝娇喘喷水9色精品| 国内精品宾馆在线| 免费看a级黄色片| 欧美成人午夜免费资源| 床上黄色一级片| 日日摸夜夜添夜夜添av毛片| 91精品伊人久久大香线蕉| 亚洲av日韩在线播放| 99热这里只有是精品50| av在线天堂中文字幕| 国产精品一区二区在线观看99 | 韩国av在线不卡| 精品久久久久久久久亚洲| 最近最新中文字幕大全电影3| 男女国产视频网站| 国产精品.久久久| 好男人在线观看高清免费视频| 2022亚洲国产成人精品| 亚洲图色成人| 国产精品日韩av在线免费观看| 久久久久国产网址| 好男人在线观看高清免费视频| 亚洲乱码一区二区免费版| 别揉我奶头 嗯啊视频| 麻豆国产97在线/欧美| 伊人久久精品亚洲午夜| 男人的好看免费观看在线视频| 亚洲av中文av极速乱| 国产精品久久电影中文字幕| 国产黄a三级三级三级人| 免费看光身美女| 国语对白做爰xxxⅹ性视频网站| 日韩av在线免费看完整版不卡| 精品99又大又爽又粗少妇毛片| 中文精品一卡2卡3卡4更新| 久久久久久久久久成人| 国产精华一区二区三区| 黄片无遮挡物在线观看| 十八禁国产超污无遮挡网站| 久久综合国产亚洲精品| 亚洲电影在线观看av| 色视频www国产| 七月丁香在线播放| 91精品一卡2卡3卡4卡| av国产久精品久网站免费入址| 日韩av在线免费看完整版不卡| 蜜桃久久精品国产亚洲av| 九色成人免费人妻av| www.av在线官网国产| 中文乱码字字幕精品一区二区三区 | av国产免费在线观看| 一级爰片在线观看| 久久久精品欧美日韩精品| 女人久久www免费人成看片 | 欧美日韩精品成人综合77777| 夜夜爽夜夜爽视频| 狠狠狠狠99中文字幕| 人妻夜夜爽99麻豆av| 特大巨黑吊av在线直播| 床上黄色一级片| 国产精品一区二区三区四区免费观看| 国产真实乱freesex| 男女下面进入的视频免费午夜| 国产欧美日韩精品一区二区| 少妇猛男粗大的猛烈进出视频 | 老司机影院毛片| 一级黄片播放器| 日日撸夜夜添| 亚洲性久久影院| 禁无遮挡网站| av免费观看日本| 免费人成在线观看视频色| 一二三四中文在线观看免费高清| 边亲边吃奶的免费视频| 免费黄网站久久成人精品| 色哟哟·www| 人人妻人人澡人人爽人人夜夜 | 国产v大片淫在线免费观看| 欧美精品国产亚洲| 伦理电影大哥的女人| 国产精品美女特级片免费视频播放器| 草草在线视频免费看| 18+在线观看网站| 日韩高清综合在线| 村上凉子中文字幕在线| 国产精品麻豆人妻色哟哟久久 | 91精品国产九色| 变态另类丝袜制服| 亚洲经典国产精华液单| 午夜激情欧美在线| 免费电影在线观看免费观看| 熟妇人妻久久中文字幕3abv| 国产淫片久久久久久久久| 免费播放大片免费观看视频在线观看 | 内射极品少妇av片p| 1024手机看黄色片| 亚洲av成人精品一二三区| 少妇的逼水好多| 国产在视频线精品| av国产免费在线观看| 亚洲av中文字字幕乱码综合| 美女内射精品一级片tv| 欧美日本亚洲视频在线播放| 一级爰片在线观看| 卡戴珊不雅视频在线播放| 亚洲精品日韩在线中文字幕| 国产色爽女视频免费观看| av在线播放精品| 亚洲精品乱码久久久久久按摩| 观看免费一级毛片| 久久综合国产亚洲精品| 国产免费一级a男人的天堂| 亚洲精品乱码久久久v下载方式| 乱人视频在线观看| 日本-黄色视频高清免费观看| 91精品国产九色| 欧美一区二区国产精品久久精品| 99视频精品全部免费 在线| 嘟嘟电影网在线观看| 欧美一区二区国产精品久久精品|